Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: <scp>ERELATE</scp> Study-Reference-Cited by-同舟云学术

Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study

Published:2022-04-27 Issue:3 Volume:56 Page:463-476
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Vande Casteele Niels¹²^ORCID,Sandborn William J.¹^ORCID,Feagan Brian G.²^ORCID,Vermeire Séverine³,Dulai Parambir S.⁴,Yarur Andres⁴,Roblin Xavier⁵^ORCID,Ben‐Horin Shomron⁶,Dotan Iris⁷,Osterman Mark T.⁸,Rosario Maria⁹,Osborn Teresa McRorie¹⁰,Panes Julian¹¹,Lindner Dirk¹²^ORCID,Agboton Christian¹²

Affiliation:

1. Division of Gastroenterology, Department of Medicine University of California San Diego School of Medicine La Jolla California USA

2. Alimentiv London Ontario Canada

3. Department of Gastroenterology and Hepatology University Hospitals Leuven Leuven Belgium

4. Division of Gastroenterology and Hepatology Medical College of Wisconsin Milwaukee Wisconsin USA

5. Department of Gastroenterology and Hepatology Centre Hospitalier Universitaire de Saint‐Etienne Saint‐Priest‐en‐Jarez France

6. Department of Gastroenterology, Sheba Medical Center, Tel HaShomer, and the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

7. Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel, and the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

8. University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

9. Takeda Cambridge Massachusetts USA

10. Takeda Chicago Illinois USA

11. Department of Gastroenterology Hospital Clinic de Barcelona, IDIBAPS, CIBERehd Barcelona Spain

12. Takeda Zurich Switzerland

Funder

Takeda Pharmaceuticals North America

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16937

Reference31 articles.

1. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

2. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

3. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn’s disease after one‐year treatment period—a single center experience;Molnár T;J Gastrointestin Liver Dis,2012

4. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases

5. Clinical pharmacology considerations in biologics development

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

2. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab;Inflammatory Bowel Diseases;2024-07-02

3. “Getting the Dose Right”—Revisiting the Topic With Focus on Biologic Agents;Clinical Pharmacology & Therapeutics;2024-04-28

4. Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels;Journal of Clinical Medicine;2023-12-27

5. Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics;Journal of Clinical Medicine;2023-11-16